Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
NAS:IRIX's Cash to Debt is ranked higher than
97% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 3.18 vs. NAS:IRIX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NAS:IRIX' s Cash to Debt Range Over the Past 10 Years
Min: 0.38  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset 0.81
NAS:IRIX's Equity to Asset is ranked higher than
78% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. NAS:IRIX: 0.81 )
Ranked among companies with meaningful Equity to Asset only.
NAS:IRIX' s Equity to Asset Range Over the Past 10 Years
Min: 0.4  Med: 0.81 Max: 0.94
Current: 0.81
0.4
0.94
Interest Coverage No Debt
NAS:IRIX's Interest Coverage is ranked higher than
97% of the 230 Companies
in the Global Medical Devices industry.

( Industry Median: 71.03 vs. NAS:IRIX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:IRIX' s Interest Coverage Range Over the Past 10 Years
Min: 2.06  Med: 39.7 Max: No Debt
Current: No Debt
F-Score: 2
Z-Score: 13.16
M-Score: -2.37
WACC vs ROIC
13.09%
-1.05%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -2.19
NAS:IRIX's Operating margin (%) is ranked lower than
56% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.28 vs. NAS:IRIX: -2.19 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:IRIX' s Operating margin (%) Range Over the Past 10 Years
Min: -43.43  Med: 2.19 Max: 6.88
Current: -2.19
-43.43
6.88
Net-margin (%) -1.01
NAS:IRIX's Net-margin (%) is ranked lower than
55% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 1.87 vs. NAS:IRIX: -1.01 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:IRIX' s Net-margin (%) Range Over the Past 10 Years
Min: -40.11  Med: 5.04 Max: 23.45
Current: -1.01
-40.11
23.45
ROE (%) -1.35
NAS:IRIX's ROE (%) is ranked lower than
56% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 2.08 vs. NAS:IRIX: -1.35 )
Ranked among companies with meaningful ROE (%) only.
NAS:IRIX' s ROE (%) Range Over the Past 10 Years
Min: -87.4  Med: 7.92 Max: 33.69
Current: -1.35
-87.4
33.69
ROA (%) -1.09
NAS:IRIX's ROA (%) is ranked lower than
53% of the 330 Companies
in the Global Medical Devices industry.

( Industry Median: 0.31 vs. NAS:IRIX: -1.09 )
Ranked among companies with meaningful ROA (%) only.
NAS:IRIX' s ROA (%) Range Over the Past 10 Years
Min: -51.3  Med: 5.92 Max: 26.59
Current: -1.09
-51.3
26.59
ROC (Joel Greenblatt) (%) -6.81
NAS:IRIX's ROC (Joel Greenblatt) (%) is ranked lower than
55% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 3.07 vs. NAS:IRIX: -6.81 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:IRIX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -186.08  Med: 11.39 Max: 28.34
Current: -6.81
-186.08
28.34
Revenue Growth (3Y)(%) 2.90
NAS:IRIX's Revenue Growth (3Y)(%) is ranked lower than
55% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. NAS:IRIX: 2.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:IRIX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -21.9  Med: 4.7 Max: 24.8
Current: 2.9
-21.9
24.8
» NAS:IRIX's 10-Y Financials

Financials (Next Earnings Date: 2017-03-03)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

IRIX Guru Trades in Q4 2015

Jim Simons 246,400 sh (-3.33%)
» More
Q1 2016

IRIX Guru Trades in Q1 2016

Jim Simons 246,300 sh (-0.04%)
» More
Q2 2016

IRIX Guru Trades in Q2 2016

Jim Simons 231,100 sh (-6.17%)
» More
Q3 2016

IRIX Guru Trades in Q3 2016

Jim Simons 210,500 sh (-8.91%)
» More
» Details

Insider Trades

Latest Guru Trades with IRIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:NAS:RTIX, NAS:ACRX, NAS:CGNT, NAS:FONR, NAS:PAVM, NAS:VRAY, NAS:IRMD, NYSE:GI, NAS:CUTR, OTCBB:GTHPE, NAS:AVGR, NAS:DRAD, AMEX:CVRS, NAS:EDAP, NAS:EYES, OTCPK:QTVLF, NAS:TNDM, OTCPK:ARTH, NAS:SPNE, NAS:VIVE » details
Traded in other countries:IX4.Germany,
Iridex Corp along with its subsidiaries, is a provider of therapeutic based laser console, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology.

Iridex Corp was incorporated in California in February 1989 as IRIS Medical Instruments, Inc. In November 1995, the Company changed its name to IRIDEX Corporation and reincorporated in Delaware. It is a provider of therapeutic based laser systems, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. Its ophthalmology products consist of laser console, delivery devices and consumable instrumentation including laser probes, and are used in the treatment of serious eye diseases, including the three causes of irreversible blindness: diabetic retinopathy, glaucoma and age-related macular degeneration. In addition, its ophthalmology products are often used in vitrectomy procedures which are generally performed in the operating room and require a consumable single use intraocular laser probe to deliver the light to the back of the eye. Its laser systems consist of IQ products which include IQ 532, IQ 577 and IQ 810 laser photocoagulation systems; and its OcuLight products including OcuLight TX, OcuLight Symphony, OcuLight SL, OcuLight SLx, OcuLight GL and OcuLight GLx laser photocoagulation systems. The Company utilizes a systems approach to product design. Each system includes a console, which generates the laser energy, and a number of interchangeable peripheral delivery devices for use in specific clinical applications. Customers include research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics. The Company sells and markets its products in the United States predominantly through its direct sales force and internationally through independent distributors. The Company has been issued 28 United States patents and 14 foreign patents. The medical devices marketed and manufactured by the company are subject to extensive regulation by numerous governmental authorities, including federal, state, and foreign governmental agencies.

Ratios

vs
industry
vs
history
Forward P/E 62.50
IRIX's Forward P/E is ranked lower than
91% of the 57 Companies
in the Global Medical Devices industry.

( Industry Median: 22.57 vs. IRIX: 62.50 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 4.57
IRIX's P/B is ranked lower than
64% of the 358 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. IRIX: 4.57 )
Ranked among companies with meaningful P/B only.
IRIX' s P/B Range Over the Past 10 Years
Min: 0.41  Med: 1.82 Max: 4.75
Current: 4.57
0.41
4.75
P/S 3.35
IRIX's P/S is ranked higher than
50% of the 351 Companies
in the Global Medical Devices industry.

( Industry Median: 3.42 vs. IRIX: 3.35 )
Ranked among companies with meaningful P/S only.
IRIX' s P/S Range Over the Past 10 Years
Min: 0.11  Med: 1.36 Max: 3.58
Current: 3.35
0.11
3.58
Current Ratio 4.16
IRIX's Current Ratio is ranked higher than
72% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: 2.44 vs. IRIX: 4.16 )
Ranked among companies with meaningful Current Ratio only.
IRIX' s Current Ratio Range Over the Past 10 Years
Min: 1.02  Med: 5.08 Max: 13.85
Current: 4.16
1.02
13.85
Quick Ratio 2.48
IRIX's Quick Ratio is ranked higher than
61% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: 1.88 vs. IRIX: 2.48 )
Ranked among companies with meaningful Quick Ratio only.
IRIX' s Quick Ratio Range Over the Past 10 Years
Min: 0.62  Med: 3.65 Max: 12.23
Current: 2.48
0.62
12.23
Days Inventory 170.23
IRIX's Days Inventory is ranked lower than
66% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 134.83 vs. IRIX: 170.23 )
Ranked among companies with meaningful Days Inventory only.
IRIX' s Days Inventory Range Over the Past 10 Years
Min: 132.97  Med: 168.71 Max: 233.91
Current: 170.23
132.97
233.91
Days Sales Outstanding 63.25
IRIX's Days Sales Outstanding is ranked higher than
56% of the 274 Companies
in the Global Medical Devices industry.

( Industry Median: 68.17 vs. IRIX: 63.25 )
Ranked among companies with meaningful Days Sales Outstanding only.
IRIX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.34  Med: 61.66 Max: 84.53
Current: 63.25
58.34
84.53
Days Payable 36.12
IRIX's Days Payable is ranked lower than
72% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 57.49 vs. IRIX: 36.12 )
Ranked among companies with meaningful Days Payable only.
IRIX' s Days Payable Range Over the Past 10 Years
Min: 29.97  Med: 35.76 Max: 43.87
Current: 36.12
29.97
43.87

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.60
IRIX's 3-Year Average Share Buyback Ratio is ranked lower than
56% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. IRIX: -5.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IRIX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -6.5  Med: -2.9 Max: 1.5
Current: -5.6
-6.5
1.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 109.71
IRIX's Price/Net Cash is ranked lower than
92% of the 146 Companies
in the Global Medical Devices industry.

( Industry Median: 14.55 vs. IRIX: 109.71 )
Ranked among companies with meaningful Price/Net Cash only.
IRIX' s Price/Net Cash Range Over the Past 10 Years
Min: 2.64  Med: 5.99 Max: 250
Current: 109.71
2.64
250
Price/Net Current Asset Value 6.68
IRIX's Price/Net Current Asset Value is ranked lower than
51% of the 268 Companies
in the Global Medical Devices industry.

( Industry Median: 6.76 vs. IRIX: 6.68 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
IRIX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.73  Med: 2.08 Max: 125.71
Current: 6.68
0.73
125.71
Price/Tangible Book 4.60
IRIX's Price/Tangible Book is ranked lower than
53% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 4.38 vs. IRIX: 4.60 )
Ranked among companies with meaningful Price/Tangible Book only.
IRIX' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.65  Med: 1.95 Max: 26.83
Current: 4.6
0.65
26.83
Price/Projected FCF 4.07
IRIX's Price/Projected FCF is ranked lower than
71% of the 130 Companies
in the Global Medical Devices industry.

( Industry Median: 2.04 vs. IRIX: 4.07 )
Ranked among companies with meaningful Price/Projected FCF only.
IRIX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.78  Med: 1.95 Max: 5.44
Current: 4.07
0.78
5.44
Price/Median PS Value 2.50
IRIX's Price/Median PS Value is ranked lower than
90% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: 1.00 vs. IRIX: 2.50 )
Ranked among companies with meaningful Price/Median PS Value only.
IRIX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.11  Med: 0.99 Max: 3.26
Current: 2.5
0.11
3.26
Earnings Yield (Greenblatt) (%) -0.71
IRIX's Earnings Yield (Greenblatt) (%) is ranked higher than
51% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: -0.81 vs. IRIX: -0.71 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IRIX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -0.73  Med: 3.4 Max: 13.5
Current: -0.71
-0.73
13.5

More Statistics

Revenue (TTM) (Mil) $45.74
EPS (TTM) $ -0.04
Beta1.43
Short Percentage of Float5.58%
52-Week Range $7.50 - 16.64
Shares Outstanding (Mil)10.15

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 46 54
EPS ($) -0.06 0.25
EPS w/o NRI ($) -0.06 0.25
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:IRIX

Headlines

Articles On GuruFocus.com
IRIDEX Corp. Reports Operating Results (10-Q) Nov 04 2010 
IRIDEX Corp. Reports Operating Results (10-Q) Aug 05 2010 
IRIDEX Corp. Reports Operating Results (10-Q) May 06 2010 
IRIDEX Corp. Reports Operating Results (10-Q) Nov 12 2009 
IRIDEX Corp. Reports Operating Results (10-Q) Aug 13 2009 
IRIDEX Corp. Reports Operating Results (10-Q) May 15 2009 
IRIDEX Corp. (IRIX) CFO James H Mackaness buys 2,000 Shares Mar 13 2009 

More From Other Websites
Edited Transcript of IRIX earnings conference call or presentation 3-Nov-16 9:00pm GMT Nov 23 2016
IRIDEX CORP Financials Nov 16 2016
IRIDEX CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Nov 09 2016
IRIDEX CORP Files SEC form 10-Q, Quarterly Report Nov 07 2016
IRIDEX to Present at Upcoming Investor Conferences Nov 07 2016
IRIDEX to Present at Upcoming Investor Conferences Nov 07 2016
IRIDEX Corp. :IRIX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 7, 2016 Nov 07 2016
Iridex reports 3Q loss Nov 03 2016
Iridex reports 3Q loss Nov 03 2016
IRIDEX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Nov 03 2016
IRIDEX Reports 2016 Third Quarter, Nine-Month Results Nov 03 2016
IRIDEX Reports 2016 Third Quarter, Nine-Month Results Nov 03 2016
Q3 2016 IRIDEX Corp Earnings Release - After Market Close Nov 03 2016
IRIDEX Announces Third Quarter 2016 Conference Call and Release Date Oct 27 2016
IRIDEX Announces Third Quarter 2016 Conference Call and Release Date Oct 27 2016
IRIDEX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Oct 11 2016
IRIDEX Announces Preliminary Revenues for 2016 Third Quarter Oct 11 2016
IRIDEX Announces Preliminary Revenues for 2016 Third Quarter Oct 11 2016
IRIDEX Announces Long-Term Glaucoma Efficacy Data for Patients Treated with MicroPulse® P3 Probe... Sep 17 2016
IRIDEX Announces Long-Term Glaucoma Efficacy Data for Patients Treated with MicroPulse® P3 Probe... Sep 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)